Abstract
Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have